lunedì, 29 novembre 2021
21 Maggio 2019

Restrictions in use of tofacitinib while EMA reviews risk of blood clots in lungs

May 17, 2019 – EMA’s safety committee (PRAC) is recommending that doctors must not prescribe the 10 mg twice daily dose of tofacitinib in patients who are at high risk of blood clots in the lungs. These include patients who have heart failure, cancer, inherited blood clotting disorders or a history of blood clots, as well as patients who take combined hormonal contraceptives, are receiving hormone replacement therapy or are undergoing major surgery. In addition, doctors … (leggi tutto)